Eye Diseases Clinical Trial
Official title:
Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
The purpose of this study is to evaluate the safety and efficacy of GP-asPNA for in vivo treatment of severe antibiotic resistant bacterial keratitis.
This is a study of antisense oligonucleotides (ASOs) in adult (ages 18 to 70) participants with severe antibiotic resistant bacterial keratitis. Approximately 20 participants will be enrolled. Infectious keratitis or endophthalmitis, mainly caused by the trauma or intraocular surgical operation, has posed a grave threat to human vision health. Among them, infectious keratitis is the most common blinding keratopathy in developing countries. We develop a novel kind of Trojan strategy to specifically deliver ASOs into diverse bacteria rather than mammalian cells through the bacterial-specific ATP-binding cassette (ABC) sugar transporter. Compared with their cell-penetrating peptide counterparts, the antisense peptide nucleic acid modified with glucose polymer can be selectively internalized into human-derived multidrug- resistant Escherichia coli and methicillin-resistant Staphylococcus aureus, and they display a much higher uptake rate. The follow-up period was 90 days, and the patients will be followed up 1 days, 3±1 days, 7±1 days, 14±2 days, 30±2 days, and 90±5 days after treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05414994 -
Assessment of the Ocular Microbiome in Health and Disease
|
||
| Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
| Completed |
NCT02811692 -
Study for Collection of Aflibercept Data in Routine Practice
|
||
| Recruiting |
NCT06045299 -
Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia
|
Phase 3 | |
| Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
| Completed |
NCT04799704 -
Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic Patients.
|
||
| Recruiting |
NCT05876689 -
Swept Source OCT Imaging With the DREAM VG-OCT
|
||
| Active, not recruiting |
NCT04123626 -
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04150432 -
Correlation Between Exhaled Propofol Concentration With Plasma Concentration in Children
|
N/A | |
| Not yet recruiting |
NCT05550740 -
Repeated Low-Level Red-Light Therapy for Shortening Axial Length
|
N/A | |
| Completed |
NCT02332343 -
Sparing of the Fovea in Geographic Atrophy Progression
|
N/A | |
| Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
| Terminated |
NCT01225146 -
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
|
Phase 1 | |
| Completed |
NCT00333203 -
Next Generation Ophthalmic Irrigating Solution Posterior Segment Study
|
Phase 3 | |
| Not yet recruiting |
NCT05565547 -
Multimodal Equipment for Teleophthalmology Assessment (META)
|
||
| Recruiting |
NCT05158699 -
Effectiveness of Periocular Drug Injection in CATaract Surgery
|
Phase 3 | |
| Recruiting |
NCT06112340 -
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
|
Phase 2/Phase 3 | |
| Completed |
NCT05211089 -
Manual Versus Automated Choroidal Thickness Measurements Using Swept-source Anterior Segment OCT
|
||
| Not yet recruiting |
NCT06070467 -
Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases
|
||
| Completed |
NCT02946879 -
Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)
|